SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants,...
Read More Details
Finally We wish PressBee provided you with enough information of ( YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR )
Also on site :
- The 36 US bases on the frontline of Iranian retribution
- NATO leaders gather Tuesday for what could be a historic summit, or one marred by divisions
- SMB-focused Finom closes €115M as European fintech heats up